These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 38885778)
1. Low-dose doxorubicin loaded extracellular vesicles combined Fas/FasL pathway-mediated chemo-sensitization and immunotherapy against tumor. Wang F; Qin S; Zhang J; Huang M; Liu Q; Xu P; Hu Y Int J Pharm; 2024 Jul; 660():124349. PubMed ID: 38885778 [TBL] [Abstract][Full Text] [Related]
2. Involvement of doxorubicin-induced Fas expression in the antitumor effect of doxorubicin on Lewis lung carcinoma in vivo. Yoshimoto Y; Kawada M; Ikeda D; Ishizuka M Int Immunopharmacol; 2005 Feb; 5(2):281-8. PubMed ID: 15652759 [TBL] [Abstract][Full Text] [Related]
3. Fas/FasL-dependent and -independent activation of caspase-8 in doxorubicin-treated human breast cancer MCF-7 cells: ADAM10 down-regulation activates Fas/FasL signaling pathway. Liu WH; Chang LS Int J Biochem Cell Biol; 2011 Dec; 43(12):1708-19. PubMed ID: 21854868 [TBL] [Abstract][Full Text] [Related]
4. Strategy to enhance efficacy of doxorubicin in solid tumor cells by methyl-β-cyclodextrin: Involvement of p53 and Fas receptor ligand complex. Mohammad N; Singh SV; Malvi P; Chaube B; Athavale D; Vanuopadath M; Nair SS; Nair B; Bhat MK Sci Rep; 2015 Jul; 5():11853. PubMed ID: 26149967 [TBL] [Abstract][Full Text] [Related]
5. Doxorubicin sensitizes human tumor cells to NK cell- and T-cell-mediated killing by augmented TRAIL receptor signaling. Wennerberg E; Sarhan D; Carlsten M; Kaminskyy VO; D'Arcy P; Zhivotovsky B; Childs R; Lundqvist A Int J Cancer; 2013 Oct; 133(7):1643-52. PubMed ID: 23504627 [TBL] [Abstract][Full Text] [Related]
6. Acylated Ghrelin Protects the Hearts of Rats from Doxorubicin-Induced Fas/FasL Apoptosis by Stimulating SERCA2a Mediated by Activation of PKA and Akt. Shati AA; Dallak M Cardiovasc Toxicol; 2019 Dec; 19(6):529-547. PubMed ID: 31093930 [TBL] [Abstract][Full Text] [Related]
7. Vulnerability of mouse cortical neurons to doxorubicin-induced apoptosis is strain-dependent and is correlated with mRNAs encoding Fas, Fas-Ligand, and metalloproteinases. Wetzel M; Tibbitts J; Rosenberg GA; Cunningham LA Apoptosis; 2004 Sep; 9(5):649-56. PubMed ID: 15314293 [TBL] [Abstract][Full Text] [Related]
8. Extracellular vesicles derived from dendritic cells loaded with VEGF-A siRNA and doxorubicin reduce glioma angiogenesis in vitro. Shamshiripour P; Rahnama M; Nikoobakht M; Rad VF; Moradi AR; Ahmadvand D J Control Release; 2024 May; 369():128-145. PubMed ID: 38522817 [TBL] [Abstract][Full Text] [Related]
9. HPMA copolymer-bound doxorubicin induces apoptosis in human ovarian carcinoma cells by a Fas-independent pathway. Malugin A; Kopecková P; Kopecek J Mol Pharm; 2004; 1(3):174-82. PubMed ID: 15981920 [TBL] [Abstract][Full Text] [Related]
10. Doxorubicin exerts cytotoxic effects through cell cycle arrest and Fas-mediated cell death. Kim HS; Lee YS; Kim DK Pharmacology; 2009; 84(5):300-9. PubMed ID: 19829019 [TBL] [Abstract][Full Text] [Related]
11. Adhesion between EVs and tumor cells facilitated EV-encapsulated doxorubicin delivery via ICAM1. Wang S; Qiao C; Kong X; Yang J; Guo F; Chen J; Wang W; Zhang B; Xiu H; He Y; Wang J; Feng H; Cai Z Pharmacol Res; 2024 Jul; 205():107244. PubMed ID: 38821149 [TBL] [Abstract][Full Text] [Related]
12. Doxorubicin-induces NFAT/Fas/FasL cardiac apoptosis in rats through activation of calcineurin and P38 MAPK and inhibition of mTOR signalling pathways. Shati AA Clin Exp Pharmacol Physiol; 2020 Apr; 47(4):660-676. PubMed ID: 31811646 [TBL] [Abstract][Full Text] [Related]
13. Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity. Mitsiades N; Yu WH; Poulaki V; Tsokos M; Stamenkovic I Cancer Res; 2001 Jan; 61(2):577-81. PubMed ID: 11212252 [TBL] [Abstract][Full Text] [Related]
14. Biomimetic nanomedicine cocktail enables selective cell targeting to enhance ovarian Cancer chemo- and immunotherapy. Dong Z; Yang W; Zhang Y; Wang B; Wan X; Li M; Chen Y; Zhang N J Control Release; 2024 Sep; 373():172-188. PubMed ID: 38972639 [TBL] [Abstract][Full Text] [Related]
15. The Fas/FasL Signaling Pathway: Its Role in the Metastatic Process and as a Target for Treating Osteosarcoma Lung Metastases. Koshkina N; Yang Y; Kleinerman ES Adv Exp Med Biol; 2020; 1258():177-187. PubMed ID: 32767242 [TBL] [Abstract][Full Text] [Related]
16. Reprogramming the T cell response to cancer by simultaneous, nanoparticle-mediated PD-L1 inhibition and immunogenic cell death. Phung CD; Nguyen HT; Choi JY; Pham TT; Acharya S; Timilshina M; Chang JH; Kim JH; Jeong JH; Ku SK; Choi HG; Yong CS; Kim JO J Control Release; 2019 Dec; 315():126-138. PubMed ID: 31672625 [TBL] [Abstract][Full Text] [Related]
17. Myeloid-derived suppressor cells express the death receptor Fas and apoptose in response to T cell-expressed FasL. Sinha P; Chornoguz O; Clements VK; Artemenko KA; Zubarev RA; Ostrand-Rosenberg S Blood; 2011 May; 117(20):5381-90. PubMed ID: 21450901 [TBL] [Abstract][Full Text] [Related]
18. An "eat me" combinatory nano-formulation for systemic immunotherapy of solid tumors. Abdel-Bar HM; Walters AA; Lim Y; Rouatbi N; Qin Y; Gheidari F; Han S; Osman R; Wang JT; Al-Jamal KT Theranostics; 2021; 11(18):8738-8754. PubMed ID: 34522209 [No Abstract] [Full Text] [Related]
19. Nanoparticle-directed sub-cellular localization of doxorubicin and the sensitization breast cancer cells by circumventing GST-mediated drug resistance. Zeng X; Morgenstern R; Nyström AM Biomaterials; 2014 Jan; 35(4):1227-39. PubMed ID: 24210875 [TBL] [Abstract][Full Text] [Related]
20. Cardiac-targeted expression of soluble fas attenuates doxorubicin-induced cardiotoxicity in mice. Niu J; Azfer A; Wang K; Wang X; Kolattukudy PE J Pharmacol Exp Ther; 2009 Mar; 328(3):740-8. PubMed ID: 19066339 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]